1923
Kenji Yamauchi founded Yamanouchi Yakuhin Shokai in Osaka.
Changed the name to Yamanouchi Pharmaceutical Co., Ltd. in 1940, Moves the head office to Tokyo in 1942
Changed the name to Yamanouchi Pharmaceutical Co., Ltd. in 1940, Moves the head office to Tokyo in 1942
1970
Launched antibiotic drug "Josamycin"
1981
Launched "Perdipine," an agent for the treatment of hypertension
1985
Launched "Gaster," an H2 reseptor antagonist diseases/gastritis
Currently sold in more than 100 countries
Currently sold in more than 100 countries
1986
Established Yamanouchi Ireland Co., Ltd. in Europe
The first overseas production base for active pharmaceutical ingredients
The first overseas production base for active pharmaceutical ingredients
1989
Tsukuba laboratory completed
1990
Acquired the pharmaceutical division of Royal Gist Brocades (Netherlands)
1993
Launched "Harnal"
Currently sold in more than 90 countries
Currently sold in more than 90 countries
1994
Established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China
2000
Launched "Lipitor," an agent to treat hypercholesterolemia
2001
Established Yamanouchi Pharma America, Inc. in the U.S.
Sales base of the company in the U.S.
Sales base of the company in the U.S.
2004
Launched "Vesicare," an agent for overactive bladder treatment, in Europe
Launched in the U.S. as well in 2005
OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.
Launched in the U.S. as well in 2005
OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.
2005
Apr. 1, 2005 Astellas Pharma Inc. was established
